Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov 29;13(11):e064541.
doi: 10.1136/bmjopen-2022-064541.

Risk of major adverse cardiovascular events associated with elevated low-density lipoprotein cholesterol in a population with atherosclerotic cardiovascular disease with and without type 2 diabetes: a UK database analysis using the Clinical Practice Research Datalink

Christopher Ll Morgan  1 , Adeline Durand  2 , Terry McCormack  3 , Elizabeth Hughes  4 , Thomas R Berni  5 , Raquel Lahoz  6
Affiliations

Risk of major adverse cardiovascular events associated with elevated low-density lipoprotein cholesterol in a population with atherosclerotic cardiovascular disease with and without type 2 diabetes: a UK database analysis using the Clinical Practice Research Datalink

Christopher Ll Morgan et al. BMJ Open. .

Abstract

Objectives: To estimate the 12-month probabilities of major adverse cardiovascular events (MACE) and non-cardiovascular death in patients with atherosclerotic cardiovascular disease (ASCVD) and elevated low-density lipoprotein cholesterol (LDL-C).

Design: A retrospective database analysis.

Setting: UK primary care.

Participants: Patients were selected from the Clinical Practice Research Datalink (Aurum) linked to Hospital Episode Statistics inpatient and Office of National Statistics mortality datasets. Patients with an ASCVD diagnosis between 01 January 2010 and 31 May 2018 and LDL-C ≥2.6 mmol/L were selected.

Primary outcomes: Primary outcomes were 12-month risk of (1) MACE (composite of revascularisation, unstable angina, non-fatal myocardial infarction, non-fatal stroke and cardiovascular death) and (2) non-cardiovascular mortality. Kaplan-Meier survival analysis estimated the probability of each outcome. A Cox proportional hazards model explored covariates associated with MACE.

Results: Of 102 245 study patients, 16 501 (16.1%) had a diagnosis of type 2 diabetes (T2DM). 65.5% of those with and 49.9% of those without T2DM had a lipid-lowering therapy (LLT) 6 months prior to index diagnosis. Twelve-month probability of MACE was 7.9% for non-T2DM and 11.8% for T2DM. LDL-C was significantly associated with risk of MACE (HR=1.19 (95% CI 1.16 to 1.22) per 1 mmol/L). History of acute coronary syndrome, other coronary heart disease, stroke and T2DM significantly increased the risk of MACE. Ezetimibe (0.88 (95% CI 0.79 to 0.99)) and low-intensity statins (0.88 (95% CI 0.79 to 0.97)) were associated with reduced 12-month MACE risk.and low-intensity statins 0.88 (95% CI 0.79 to 0.97) CONCLUSION: We confirmed the association between elevated LDL-C and MACE. Many patients with ASCVD and elevated LDL-C were untreated with LLT. With the increasing demands on general practitioners, initiatives aimed at improving identification and treatment of at-risk patients within primary care should be considered.

Keywords: Low-density lipoprotein cholesterol; Major adverse cardiovascular events; atherosclerotic cardiovascular disease; lipid-lowering therapy; type 2 diabetes.

PubMed Disclaimer

Conflict of interest statement

Competing interests: AD is an employee of Novartis UK, and RL is an employee of Novartis AG, Switzerland. CLM and TB are employees of Human Data Sciences, a research consultancy that receives funding from a wide range of organisations including those from the pharmaceutical industry. Human Data Sciences received funding from Novartis UK to conduct this study. TM has received industry sponsorship for personal financial gain from AMGEN, Daiichi Sankyo, Novartis and Sanofi-Aventis. EH has received industry sponsorship for personal financial gain from MGEN, Daiichi Sankyo, Novartis and Sobi.

Figures

Figure 1
Figure 1
Selection of atherosclerotic cardiovascular disease cohort with elevated low-density lipoprotein cholesterol.
Figure 2
Figure 2
Kaplan-Meier curves showing time to event with 95% CIs for primary and secondary outcomes by type 2 diabetes status.
See this image and copyright information in PMC

References

    1. Abdullah SM, Defina LF, Leonard D, et al. . Long-term association of low-density lipoprotein cholesterol with cardiovascular mortality in individuals at low 10-year risk of atherosclerotic cardiovascular disease. Circulation 2018;138:2315–25. 10.1161/CIRCULATIONAHA.118.034273 - DOI - PubMed
    1. Ballantyne CM, Grundy SM, Oberman A, et al. . Hyperlipidemia: diagnostic and therapeutic perspectives. J Clin Endocrinol Metab 2000;85:2089–112. 10.1210/jcem.85.6.6642-1 - DOI - PubMed
    1. Hans-Willi P. Low density lipoprotein cholesterol and coronary heart disease. Eur Cardiol Rev 2005;1:1–16. 10.15420/ecr.2005.1c - DOI
    1. Baigent C, F, Catapano AL, Koskinas KC, et al. . ESC scientific document group. 2019 ESC/EAS guidelines for the management of dyslipidaemias:lipid modification to reduce cardiovascular risk. Eur Heart J 2020;111:88. - PubMed
    1. Treatment Trialists’ Collaboration . Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet 2019;393:407–15. - PMC - PubMed

Publication types

MeSH terms

Substances